Valve Regurgitation With LV Dysfunction How Did We Get There?∗ by Enriquez-Sarano, Maurice
J A C C : C A R D I O V A S C U L A R I M A G I N G V O L . 8 , N O . 1 , 2 0 1 5
ª 2 0 1 5 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 8 X / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j c m g . 2 0 1 4 . 1 0 . 0 0 8EDITORIAL COMMENTValve Regurgitation With LV Dysfunction
How Did We Get There?*Maurice Enriquez-Sarano, MDV alve regurgitations can cause left ventricular(LV) dysfunction. Historically, we came tothis conclusion by observing poor results of
valvular surgery, whereby patients who presented
with post-operative heart failure often had normally
functioning prostheses or repairs but a poorly con-
tracting left ventricle. The advent of echocardiogra-
phy allowed more generalized measurement of LV
characteristics and the conﬁrmation that LV dysfunc-
tion affects patients with mitral regurgitation (MR)
or aortic regurgitation (AR). The consequences of LV
dysfunction are serious, causing excess rates of heart
failure and death after “successful” surgery. The
question of whether surgery itself caused the LV
dysfunction was promptly resolved by observing
that patients with post-operative LV dysfunction had
presented, in the vast majority, with worse LV charac-
teristics before the operation. Subsequently, it was
shown that signs of LV dysfunction also had severe
outcome implications under medical management,
while patients were waiting for the “optimal” timing
of surgery. The quest to understand how we got to
the point of overt LV dysfunction has been frustrating
because of the complex hemodynamics of valve regur-
gitations, the complexity of assessing true LV contrac-
tility, and the limited knowledge of the biochemical
and genetic factors that govern a “good” versus a
“bad” left ventricle. In this issue of iJACC, Kusunose
et al. (1) attempt to uncover the link between overload
and progression of LV dysfunction in patients with
organic MR and AR.SEE PAGE 14The study (1) was based on cohorts of patients with
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to the contents of this paper to disclose.matched according to age and regurgitant volume
and who had at least 1 follow-up evaluation by echo-
cardiography 1 year later (and at subsequent years for
some patients). The authors analyzed rates of decline
of LV function, measured by using various indices,
volumes, ejection fractions, end-systolic stress and
pressure/volume ratios, and preload recruitable
stroke work, by direct comparison and by complex
mixed models to account for those lost to follow-up
over time. The results showed that a decline in LV
function was observed only in patients with severe
regurgitation, deﬁned by a regurgitant volume
$30 ml/m2, and that rates of decline were similar in
MR and AR. Based on their data, the authors suggest
that yearly echocardiographic monitoring may be
excessive in patients with moderate regurgitation but
is reasonable in patients with severe regurgitation.
The contributions of this study (1) to our knowledge
of valve regurgitations are important. First, the de-
monstration that larger volume overload, measured
by using the regurgitant volume, is a key determinant
of LV function deterioration was not previously
proven, although it was perceived as such because
patients with moderate regurgitation rarely develop
LV dysfunction. This ﬁnding adds proof to the existing
literature based on quantiﬁed valvular regurgitations,
that severity of AR (2) and of MR (3) is a major deter-
minant of clinical outcome under medical manage-
ment and thereby reinforces the mandate to use these
quantitative measures in clinical practice. Second,
measures of AR and MR severity indexed to body
surface area have been used but are not yet recom-
mended. This point is important because analysis of
valve regurgitations in women has shown that women
have smaller bodies and left ventricles and that ab-
solute measurements nonindexed to their body size
are part of underestimating their valve disease
severity and of their worse outcome compared with
men. Although this key clinical process has to be
reﬁned (i.e., determining if body surface area or
another measure for indexation should be used), it
must be present in the mind of clinicians. Third, the
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25equal LV progression of AR and MR is more disput-
able. It has long been known that LV response to
regurgitation is different in MR cases versus AR cases,
which have a higher afterload and generally more
severe LV enlargement (4). This difference was also
demonstrated by the study’s contrasting baseline data
of AR and MR.
This third point leads to a discussion of the limita-
tions of the study (1). Indeed, age-matching of AR and
MR patients who present in clinical practice at
different ages (2,3) may bias the similarity to real-life
LV dysfunction progression. Furthermore, follow-up
was no more than 1 or 2 years in a large proportion
of the patients with severe regurgitation, reducing the
power to detect a difference. Also, selection of pa-
tients on the basis of performance of exercise testing,
although no exercise data were analyzed, probably
biases the study in contrast to the general pool of AR
and MR. Finally, valve regurgitations generally prog-
ress with increasing regurgitant volume (5), which
was not accounted for in the study. Hence, the
conclusion that MR and AR display similar progres-
sion of LV dysfunction is tenuous and warrants longer
and more comprehensive data in future studies.
What are the take-home messages of this study (1)
as integrated with the literature? First, it is reason-
able to determine the frequency of follow-up ofpatients with AR and MR on the basis of quantitative
measures of regurgitation. We use a general rule in
patients with moderate regurgitation, based on
average progression that would bring the patient close
to severe regurgitation. New data on regurgitation
progression are needed to reﬁne the timing of
follow-up. Second, body size should be taken into
account in the assessment of regurgitation severity
and consequences. New research is necessary to
specify how best to achieve body size indexation.
Third, quantitative assessment of valve regurgitations
is a must, and the present study shows again that it is
feasible. Once the numbers are obtained, interpreta-
tion in the speciﬁc context of the patient and his or her
valve disease is essential. Fourth, the occurrence of
LV dysfunction is rare and is far from being the
single marker of poor outcome. A wide array of such
markers of poor outcome under medical management
should be gathered in patients with valve regurgita-
tions. In turn, this comprehensive approach will allow
the major outcome beneﬁts of early surgery to be
acknowledged (6).
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